PubmedID,Title,Publication Date,Non-academic Author(s),Company Affiliation(s),Corresponding Author Email
38304857,"RELAY, Erlotinib Plus Ramucirumab in Untreated, ",2024,"Carlsen, Michelle","Eli Lilly and Company, Indianapolis, Indiana.",None
38245456,Brief Report: Updated Efficacy and Safety Data From an Integrated Analysis of Entrectinib in Locally Advanced/Metastatic ROS1 Fusion-Positive Non-Small-Cell Lung Cancer.,2024,"Zeuner, Harald; Xue, Cloris","F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Mississauga, Canada.",matthew.krebs@manchester.ac.uk.
38190787,"EGFR-mutation testing, treatment patterns and clinical outcomes in patients with stage IB-IIIA non-small cell lung cancer in Norway-a nationwide cohort study.",2024,"Conte, Simona; Frederiksen, Line Elmerdahl; Aarøe, Jørgen","Medical, Biopharmaceuticals, AstraZeneca, Stockholm, Sweden.; Medical, Biopharmaceuticals, AstraZeneca, Copenhagen, Denmark.; Medical, Biopharmaceuticals, AstraZeneca, Oslo, Norway.",espen.enerly@kreftregisteret.no.
38159809,"Pembrolizumab With or Without Lenvatinib for First-Line Metastatic NSCLC With Programmed Cell Death-Ligand 1 Tumor Proportion Score of at least 1% (LEAP-007): A Randomized, Double-Blind, Phase 3 Trial.",2024,"Okpara, Chinyere E; Dutcus, Corina; Zimmer, Zachary; Samkari, Ayman; Bhagwati, Niyati","Eisai Ltd., Hatfield, United Kingdom.; Eisai Inc., Nutley, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.; Merck & Co., Inc., Rahway, New Jersey.",chihyang@ntu.edu.tw.
38110665,A phase Ib/II study of cadonilimab (PD-1/CTLA-4 bispecific antibody) plus anlotinib as first-line treatment in patients with advanced non-small cell lung cancer.,2024,"Li, Baiyong; Xia, Yu","Akeso Biopharma, Inc, Zhongshan, China.; Akeso Biopharma, Inc, Zhongshan, China.",wulin-calf@vip.163.com.
38100106,Biomarker Testing in Patients With Unresectable Advanced or Recurrent Non-Small Cell Lung Cancer.,2023/Dec/01,"Nishimura, Kunihiro; Hiraoka, Manabu","Xcoo Inc, Tokyo, Japan.; Japan Medical Affairs, Japan Oncology Business Unit, Takeda Pharmaceutical Company Limited, Tokyo, Japan.",None
38049664,The role of APOBEC3B in lung tumor evolution and targeted cancer therapy resistance.,2024,"McCoach, Caroline E","Genentech Inc, South San Francisco, CA, USA.",trever.bivona@ucsf.edu.
38035705,Circular RNA in Non-small Cell Lung Carcinoma: Identification of Targets and New Treatment Modalities.,2023,"Weidle, Ulrich H; Birzele, Fabian","Roche Pharma Research and Early Development, Roche Innovation Center Munich, Penzberg, Germany; weidle49@t-online.de.; Roche Pharma Research and Early Development, Pharmaceutical Sciences, Roche Innovation Center Basel, Basel, Switzerland fabian.birzele@roche.com.",fabian.birzele@roche.com.
38025806,Real-world treatment patterns and survival outcomes for patients with stage III non-small cell lung cancer in Spain: a nationwide cohort study.,2023/Oct/31,"Penrod, John; Vo, Lien","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",None
38001689,C-Reactive Protein as an Early Predictor of Efficacy in Advanced Non-Small-Cell Lung Cancer Patients: A Tumor Dynamics-Biomarker Modeling Framework.,2023/Nov/15,"Pérez-Pitarch, Alejandro","Translational Medicine & Clinical Pharmacology, Boehringer Ingelheim Pharma GmbH & Co. KG, 55216 Ingelheim am Rhein, Germany.",None
38001589,Amivantamab Compared with Real-World Physician's Choice after Platinum-Based Therapy from a Pan-European Chart Review of Patients with Lung Cancer and Activating ,2023/Nov/08,"Diels, Joris; Schioppa, Claudio A; Sermon, Jan; Rahhali, Nora; Adamczyk, Agnieszka; Penton, James","Janssen Pharmaceutica NV, 2340 Beerse, Belgium.; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.; Janssen Pharmaceutica NV, 2340 Beerse, Belgium.; Janssen-Cilag Ltd., 92130 Issy-les-Moulineaux, France.; Janssen-Cilag Ltd., 28042 Madrid, Spain.; Janssen-Cilag Ltd., High Wycombe HP12 4EG, UK.",None
37992595,"Patient-reported outcomes with durvalumab, with or without tremelimumab, plus chemotherapy as first-line treatment for metastatic non-small-cell lung cancer (POSEIDON).",2023,"Alatorre-Alexander, Jorge; Araujo, Luiz Henrique","Health Pharma Professional Research, Mexico City, Mexico.; Instituto Nacional de Cancer-INCA, Rio de Janeiro, Brazil.",egaron@mednet.ucla.edu.
37966566,Clinical Characteristics of Patients with Advanced ALK-Translocated Non-small Cell Lung Cancers and Long-Term Responses to Crizotinib (CRIZOLONG GFPC 05-19 Study).,2023,"Dhamelincourt, Estelle","Institut de Cancérologie, Hôpital Morvan, CHU de Brest, Brest, France. Estelle.dhamelincourt@chu-brest.fr.",Estelle.dhamelincourt@chu-brest.fr.
37933916,"Association between treatment and improvements in overall survival of patients with advanced/metastatic non-small cell lung cancer since 2011: A study in the United States, Canada, and Germany using retrospective real-world databases.",2024/Feb/15,"Froelich, Carolin","Roche Pharma AG, Grenzach-Wyhlen, Germany.",None
37916501,Pralsetinib in patients with RET fusion-positive non-small-cell lung cancer: A plain language summary of the ARROW study.,2024,"Smoljanovic, Vlatka; Rahman, Ahmadur; Zalutskaya, Alena; Louie-Gao, Melinda; Boral, Andy L","F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; F. Hoffmann-La Roche, Ltd, Basel, Switzerland.; Blueprint Medicines Corporation, Cambridge, MA, USA.; Blueprint Medicines Corporation, Cambridge, MA, USA.; Blueprint Medicines Corporation, Cambridge, MA, USA.",None
37877248,Comparison of two-stage and joint TGI-OS modeling using data from six atezolizumab clinical studies in patients with metastatic non-small cell lung cancer.,2024,"Chan, Phyllis; Jin, Jin Y; Bruno, René","Clinical Pharmacology, Genentech, South San Francisco, California, USA.; Clinical Pharmacology, Genentech, South San Francisco, California, USA.; Clinical Pharmacology, Genentech-Roche, Marseille, France.",None
37860193,Significant changes in advanced lung cancer survival during the past decade in Hungary: impact of modern immunotherapy and the COVID-19 pandemic.,2023,"Kiss, Zoltán; Hódi, Gábor; Polányi, Zoltán; Kovács, Krisztina; Knollmajer, Kata; Szabó, Tamás G; Berta, Andrea; Rokszin, György; Abonyi-Tóth, Zsolt; Barcza, Zsófia","MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; MSD Pharma Hungary Ltd, Budapest, Hungary.; RxTarget Ltd., Szolnok, Hungary.; RxTarget Ltd., Szolnok, Hungary.; Syntesia Ltd, Budapest, Hungary.",None
37839252,Characterization of 164 patients with NRAS mutated non-small cell lung cancer (NSCLC).,2023,"Munck, Camille","Pneumologie, Hôpital Saint Vincent de Paul, Lille, France.",simon.baldacci@univ-lille2.fr.
37814061,ctDNA response after pembrolizumab in non-small cell lung cancer: phase 2 adaptive trial results.,2023,"Sausen, Mark","Personal Genome Diagnostics (LabCorp), Baltimore, MD, USA.",jdancey@ctg.queensu.ca.
37792849,Allogeneic hematopoietic cell transplantation for blastic plasmacytoid dendritic cell neoplasm: a CIBMTR analysis.,2023/Nov/28,"Michelis, Fotios V; Joseph, Jacinth","Allogeneic Blood and Marrow Transplant Program, Princess Margaret Cancer Centre, Toronto, Canada.; Methodist Healthcare Blood and Marrow Transplant Center, Memphis, TN.",None
37773318,ALK fusions in the pan-cancer setting: another tumor-agnostic target?,2023/Sep/29,"Janku, Filip","Monte Rosa Therapeutics, Boston, MA, USA.",rkurzrock@mcw.edu.
37768658,Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.,2023/Nov/01,"Bedard, Philippe L; Wu, Benjamin; Patil, Namrata S; Jin, Yanling; Hoang, Tien; Mendus, Diana; Wen, Xiaohui; Meng, Raymond","Princess Margaret Cancer Center, Toronto, Ontario, Canada.; Clinical Pharmacology, Genentech Inc, South San Francisco, California.; Biomarkers, Genentech Inc, South San Francisco, California.; Biostatistics, F. Hoffmann-La Roche Ltd, Mississauga, Ontario, Canada.; Clinical Science, Genentech Inc, South San Francisco, California.; Clinical Science, Genentech Inc, South San Francisco, California.; Safety Science, Genentech Inc, South San Francisco, California.; Clinical Science, Genentech Inc, South San Francisco, California.",None
37754495,Use of Drugs in Clinical Practice and the Associated Cost of Cancer Treatment in Adult Patients with Solid Tumors: A 10-Year Retrospective Cohort Study.,2023/Aug/30,"Tomás-Guillén, Elena; Monterde, Josep","Asserta Global Healthcare Solutions, Sant Quirze del Vallés, E-08192 Barcelona, Spain.; Asserta Global Healthcare Solutions, Sant Quirze del Vallés, E-08192 Barcelona, Spain.",None
37731641,Clinical outcomes of ramucirumab plus docetaxel in the treatment of patients with non-small cell lung cancer after immunotherapy: a systematic literature review.,2023,"Visseren-Grul, Carla; Rizzo, Maria Teresa; Puri, Tarun; Chenji, Suresh","Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.; Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN, United States.; Eli Lilly and Company, Bengaluru, Karnataka, India.",None
37699333,Tumor dynamics in patients with solid tumors treated with pembrolizumab beyond disease progression.,2023/Sep/11,"Topp, Brian G; Mayawala, Kapil; De Alwis, Dinesh P; Rubin, Eric; Snyder, Alexandra","Merck & Co., Inc, Rahway, NJ, USA. Electronic address: brian.topp@merck.com.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.; Merck & Co., Inc, Rahway, NJ, USA.",brian.topp@merck.com.
37677918,"A multicenter, open-label phase Ib/II study of cadonilimab (anti PD-1 and CTLA-4 bispecific antibody) monotherapy in previously treated advanced non-small-cell lung cancer (AK104-202 study).",2023,"Song, Weifeng; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Yu","Akeso Biopharma, Inc., Guangzhou, China.; Akeso Biopharma, Inc., Guangzhou, China.; Akeso Biopharma, Inc., Guangzhou, China.; Akeso Biopharma, Inc., Guangzhou, China.",zhangli@sysucc.org.cn.
37606995,Somatic rearrangements causing oncogenic ectodomain deletions of FGFR1 in squamous cell lung cancer.,2023/Nov/01,"Menon, Roopika; Heuckmann, Johannes M","DISCO Pharmaceuticals GmbH, Cologne, Germany.; DISCO Pharmaceuticals GmbH, Cologne, Germany.",None
37605861,Effectiveness of crizotinib in patients with ,2023,"Emir, Birol; Wiltshire, Robin","Pfizer Inc., 235 E 42nd St, New York, NY 10017, USA.; Pfizer Inc., 235 E 42 St, New York, NY 10017, USA.",None
37593227,"AK112, a novel PD-1/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial.",2023,"Li, Wenting; Song, Weifeng; Wang, Zhongmin Maxwell; Li, Baiyong; Xia, Michelle","Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.; Akeso Biopharma, Inc., No, 6, Shennong Road, Torch Development Zone, Zhongshan, Guangdong Province, PR China.",None
37548831,First-line nivolumab plus ipilimumab in metastatic non-small cell lung cancer: 5-year outcomes in Japanese patients from CheckMate 227 Part 1.,2023,"Li, Li; Gupta, Ravi G; Bushong, Judith","Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Bristol Myers Squibb, Princeton, NJ, USA.",mnishio@jfcr.or.jp.
37536935,Circulating immune cell dynamics as outcome predictors for immunotherapy in non-small cell lung cancer.,2023,"Marcos Rubio, Alvaro; Everaert, Celine; Van Damme, Eufra; De Preter, Katleen","VIB UGent Center for Medical Biotechnology, Ghent, Belgium.; VIB UGent Center for Medical Biotechnology, Ghent, Belgium.; VIB UGent Center for Medical Biotechnology, Ghent, Belgium.; VIB UGent Center for Medical Biotechnology, Ghent, Belgium.",karim.vermaelen@ugent.be.
37516008,Pan-tumor survey of RET fusions as detected by next-generation RNA sequencing identified RET fusion positive colorectal carcinoma as a unique molecular subset.,2023,"Raez, Luis E","Memorial Healthcare System, Pembroke Pines, FL, USA.",nagasakm@hs.uci.edu.
37507657,A phase Ib/II study of galunisertib in combination with nivolumab in solid tumors and non-small cell lung cancer.,2023/Jul/28,"Zhao, Yumin; Gueorguieva, Ivelina; Man, Michael; Estrem, Shawn T; Liu, Jiangang; Avsar, Emin; Lin, Wen Hong; Benhadji, Karim A; Gandhi, Leena; Guba, Susan C","Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Bristol Myers Squibb, Princeton, NJ, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.; Eli Lilly and Company, Indianapolis, IN, USA.",esnadal@iconcologia.net.
37499521,A phase I/IB trial of binimetinib in combination with erlotinib in NSCLC harboring activating KRAS or EGFR mutations.,2023,"Sansil, Samer; Neuger, Anthony","Cancer Pharmacokinetics & Pharmacodynamics Core, Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL 33612, USA.; Cancer Pharmacokinetics & Pharmacodynamics Core, Moffitt Cancer Center, 12902 Magnolia Dr., Tampa, FL 33612, USA.",andreas.saltos@moffitt.org.
37490292,Association of Circulating Tumor DNA Testing Before Tissue Diagnosis With Time to Treatment Among Patients With Suspected Advanced Lung Cancer: The ACCELERATE Nonrandomized Clinical Trial.,2023/Jul/03,"Pipinikas, Christodoulos; Howarth, Karen; Ambasager, Bana","Inivata Ltd, Cambridge, United Kingdom.; Inivata Ltd, Cambridge, United Kingdom.; Inivata Ltd, Cambridge, United Kingdom.",None
37451931,"MET Exon 14 Skipping in NSCLC: A Systematic Literature Review of Epidemiology, Clinical Characteristics, and Outcomes.",2023,"Vioix, Helene; Pfeiffer, Boris M; Campden, Rhiannon I; Chen, Zhiyuan; Heeg, Bart","The Healthcare Business of Merck KGaA, Darmstadt, Germany.; The Healthcare Business of Merck KGaA, Darmstadt, Germany.; Ingress Health, A Cytel Company, Rotterdam, The Netherlands.; Ingress Health, A Cytel Company, Rotterdam, The Netherlands.; Ingress Health, A Cytel Company, Rotterdam, The Netherlands.",mazieres.j@chu-toulouse.fr.
37451404,Neoadjuvant Targeted Therapy in Resectable NSCLC: Current and Future Perspectives.,2023,"Bara, Ilze; Kurtsikidze, Nino; Schulze, Katja; Ngiam, Celina","US Medical Affairs, Genentech, Inc., South San Francisco, California.; Global Product Development and Medical Affairs Oncology, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Translational Medicine, Oncology Biomarker Development, Genentech, Inc., South San Francisco, California.; US Medical Affairs, Genentech, Inc., South San Francisco, California.",jaymoonlee@mednet.ucla.edu.
37423228,"First-line atezolizumab monotherapy versus single-agent chemotherapy in patients with non-small-cell lung cancer ineligible for treatment with a platinum-containing regimen (IPSOS): a phase 3, global, multicentre, open-label, randomised controlled study.",2023/Aug/05,"Liu, Geoffrey","Medical Oncology and Hematology, Princess Margaret Cancer Centre, Toronto, ON, Canada.",sm.lee@nhs.net.
37393762,"Efficacy and safety of KN046, a novel bispecific antibody against PD-L1 and CTLA-4, in patients with non-small cell lung cancer who failed platinum-based chemotherapy: a phase II study.",2023,"Xu, Ting; Xu, Mo; Zhi, Lihua; Liu, Qing; Wang, Ni","Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Medical, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.; Biostatistic, Jiangsu Alphamab Biopharmaceuticals Co., Ltd, Suzhou, China.",caicunzhoudr@163.com.
37390764,Ramucirumab plus erlotinib versus placebo plus erlotinib in previously untreated EGFR-mutated metastatic non-small-cell lung cancer (RELAY): exploratory analysis of next-generation sequencing results.,2023,"Graham, H; Butts, B D; Visseren-Grul, C","Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.; Eli Lilly and Company, Indianapolis, USA.",egaron@mednet.ucla.edu.
37385154,A phase Ib/II dose expansion study of subcutaneous sasanlimab in patients with locally advanced or metastatic non-small-cell lung cancer and urothelial carcinoma.,2023,"Bonato, V; Damore, M A; Yang, W; Jacobs, I A; Bowers, M; Li, M","Pfizer Inc, San Diego, USA.; Pfizer Inc, San Diego, USA.; Pfizer Inc, San Diego, USA.; Pfizer Inc, New York, USA.; Pfizer Inc, Arnold, USA.; Pfizer Inc, San Francisco, USA.",mjohnson@tnonc.com.
37358877,Clinicogenomic factors and treatment patterns among patients with advanced non-small cell lung cancer with or without brain metastases in the United States.,2023/Nov/02,"Smyth, Emily Nash; John, Jincy; Tiu, Ramon V; Willard, Melinda Dale; Beyrer, Julie Kay; Bowman, Lee; Sheffield, Kristin M; Han, Yimei","Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Lilly Global Clinical Development, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Value Evidence Outcomes - Research, Indianapolis, IN 46225, USA.; Eli Lilly and Company, Statistics RWE, Indianapolis, IN 46225, USA.",None
37352588,Uptake of novel systemic therapy: Real world patterns among adults with advanced non-small cell lung cancer.,2023,"Honda, Stacey A","Hawaii Permanente Medical Group and Center for Integrated Healthcare Research, Kaiser Permanente Hawaii, Honolulu, HI, USA.",nikki.m.carroll@kp.org.
37343657,Somatic and germline ATM variants in non-small-cell lung cancer: Therapeutic implications.,2023,"Hernandez-Martinez, Juan-Manuel; Arrieta, Oscar","Thoracic Oncology Unit and Experimental Oncology Laboratory, Instituto Nacional de Cancerología de México (INCan), Mexico; CONACYT-Instituto Nacional de Cancerología, Mexico City, Mexico.; Thoracic Oncology Unit and Experimental Oncology Laboratory, Instituto Nacional de Cancerología de México (INCan), Mexico. Electronic address: ogar@unam.mx.",ogar@unam.mx.
37341856,ALK Inhibitor Treatment Patterns and Outcomes in Real-World Patients with ALK-Positive Non-Small-Cell Lung Cancer: A Retrospective Cohort Study.,2023,"Sussell, Jesse; Lin, Chia-Wei; Ogale, Sarika","Evidence for Access, Genentech Inc., South San Francisco, CA, USA.; Evidence for Access, Genentech Inc., South San Francisco, CA, USA.; Evidence for Access, Genentech Inc., South San Francisco, CA, USA.",Vivek.Rudrapatna@ucsf.edu.
37329423,"Efficacy and Tolerability of Ramucirumab Plus Erlotinib in Taiwanese Patients with Untreated, Epidermal Growth Factor Receptor-Mutated, Stage IV Non-small Cell Lung Cancer in the RELAY Study.",2023,"Jen, Min-Hua","Eli Lilly and Company, Bracknell, UK.",jyshih@ntu.edu.tw.
37324065,Analysis of real-world data to investigate evolving treatment sequencing patterns in advanced non-small cell lung cancers and their impact on survival.,2023/May/30,"Liu, Zongzhi; Lee, Kyeryoung; Cohn, David; Zhang, Mingwei; Ai, Lei; Li, Minghao; Zhang, Xingming; Jun, Tomi; Higashi, Mitchell K; Pan, Qi; Oh, William; Stolovitzky, Gustavo; Schadt, Eric; Wang, Xiaoyan; Li, Shuyu D","Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.; Sema4 Mount Sinai Genomic Inc., Stamford, CT, USA.",None
37310183,Variations in Genomic Testing in Non-small Cell Lung Carcinoma: A Healthcare Professional Survey of Current Practices in the UK.,2023/Aug/03,"Desai, Ketul",Novartis Pharmaceuticals UK Limited.,None
37306665,Understanding the patient experience and treatment benefits in patients with non-small-cell lung cancer with brain metastasis.,2023,"Vallow, Susan; Gilloteau, Isabelle; Chassot Agostinho, Andrea","Novartis Services Inc., East Hanover, New Jersey, USA.; Novartis Services Inc., East Hanover, New Jersey, USA.; Novartis Services Inc., East Hanover, New Jersey, USA.",None
37296369,Distributional Cost-Effectiveness Analysis of Treatments for Non-Small Cell Lung Cancer: An Illustration of an Aggregate Analysis and its Key Drivers.,2023,"Ramagopalan, Sreeram","Global Access, F. Hoffmann-La Roche Ltd, Grenzacherstrasse, Basel, Switzerland. s.ramagopalan@lse.ac.uk.",s.ramagopalan@lse.ac.uk.
37285629,Real-world outcomes in patients with KRAS G12C-mutated advanced non-small cell lung cancer treated with docetaxel in second-line or beyond.,2023,"Hsu, Hil; Younan, Diana; Suri, Gaurav; Chia, Victoria","Center for Observational Research, Amgen Inc., 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.; Center for Observational Research, Amgen Inc., 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.; Health Economics and Outcomes Research, Amgen Inc., 4 Uxbridge Business Park, Sanderson Road Uxbridge UB8 1DH, UK.; Center for Observational Research, Amgen Inc., 1 Amgen Center Dr, Thousand Oaks, CA 91320, USA.",jhanelle.gray@moffitt.org.
37278879,"A Phase Ib Study Assessing the Safety, Tolerability, and Efficacy of the First-in-Class Wee1 Inhibitor Adavosertib (AZD1775) as Monotherapy in Patients with Advanced Solid Tumors.",2023,"Oza, Amit; Mugundu, Ganesh","Princess Margaret Cancer Centre, Toronto, Canada.; Clinical Pharmacology and Quantitative Pharmacology, Clinical Pharmacology and Safety Sciences, AstraZeneca, Boston, MA, USA.",siqingfu@mdanderson.org.
37274265,Case Report: Complete pathologic response to neoadjuvant selpercatinib in a patient with resectable early-stage ,2023,"Szymczak, Sylwia; Szpurka, Anna M; Chao, Bo H","Loxo@Lilly, Eli Lilly and Company, Warsaw, Poland.; Loxo@Lilly, Eli Lilly and Company, Indianapolis, IN, United States.; Loxo@Lilly, Eli Lilly and Company, New York, NY, United States.",Loxo@Lilly
37268157,"IMscin001 Part 2: a randomised phase III, open-label, multicentre study examining the pharmacokinetics, efficacy, immunogenicity, and safety of atezolizumab subcutaneous versus intravenous administration in previously treated locally advanced or metastatic non-small-cell lung cancer and pharmacokinetics comparison with other approved indications.",2023,"Herraez-Baranda, L; Liu, S N; Chan, P; Shearer-Kang, E; Liu, X; Tosti, N; Zanghi, J A; Leutgeb, B","Product Development Medical Affairs Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Clinical Pharmacology, Genentech, Inc., South San Francisco, USA.; Clinical Pharmacology, Genentech, Inc., South San Francisco, USA.; Product Safety Development, Genentech, Inc., South San Francisco, CA, USA.; Data and Statistical Sciences, Genentech, Inc., South San Francisco, CA, USA.; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.; BioAnalytical Sciences, Genentech, Inc., South San Francisco, CA, USA.; Product Development Oncology, F. Hoffmann-La Roche Ltd, Basel, Switzerland.",Mburotto@bradfordhill.cl.
37186518,Efficacy and Imaging-Enabled Pharmacodynamic Profiling of KRAS G12C Inhibitors in Xenograft and Genetically Engineered Mouse Models of Cancer.,2023/Jul/05,"Lee, Catherine; Jiang, Ziyue Karen; Planken, Simon; Manzuk, Lisa K; Ortiz, Roberto; Hall, Michael; Noorbehesht, Kavon; Ram, Sripad; Affolter, Timothy; Troche, Gabriel E; Ihle, Nathan T; Johnson, Theodore; Ahn, Youngwook; Kraus, Manfred; Giddabasappa, Anand","Oncology Research and Development, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Global Science & Technology - Comparative Medicine, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Oncology Medicinal Chemistry, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Comparative Medicine, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; BioMedicine Design, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; BioMedicine Design, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Global Science & Technology - Comparative Medicine, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Drug Safety Research and Development Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Drug Safety Research and Development Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Oncology Research and Development, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Oncology Research and Development, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Medicine Design, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Target Sciences, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Oncology Research and Development, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.; Global Science & Technology - Comparative Medicine, Pfizer Inc., Worldwide Research, Development and Medical, San Diego, California.",None
37183528,Pembrolizumab plus chemotherapy in Japanese patients with metastatic squamous non-small-cell lung cancer in KEYNOTE-407.,2023,"Schwarzenberger, Paul","Merck & Co., Inc., Rahway, New Jersey, USA.",None
37182602,Combination Therapy With MDM2 and MEK Inhibitors Is Effective in Patient-Derived Models of Lung Adenocarcinoma With Concurrent Oncogenic Drivers and MDM2 Amplification.,2023,"Tirunagaru, Vijaya G; Doebele, Robert C","Rain Oncology Inc., Newark, California.; Rain Oncology Inc., Newark, California.",ladanyim@mskcc.org.
37172552,"Antibody-drug conjugates, immune-checkpoint inhibitors, and their combination in advanced non-small cell lung cancer.",2023,"Salifu, Idoko; Berraondo, Maria; Severson, Eric; Vidal, Laura; Chico, Isagani","Labcorp Drug Development Inc., Princeton, NJ, USA. Electronic address: globalclinicalmonitors@gmail.com.; Labcorp Drug Development Inc., Princeton, NJ, USA.; Labcorp Drug Development Inc., Princeton, NJ, USA.; Labcorp Drug Development Inc., Princeton, NJ, USA.; Labcorp Drug Development Inc., Princeton, NJ, USA.",scm.salifu@gmail.com.
37158938,"First-in-human phase I/Ib study of QL1706 (PSB205), a bifunctional PD1/CTLA4 dual blocker, in patients with advanced solid tumors.",2023/May/08,"Kang, Xiaoyan; Xue, Shilin","Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China.; Clinical Research Center, Qilu Pharmaceutical Co., Ltd., Jinan, 250000, China.",zhaohy@sysucc.org.cn.
37147298,Circulating tumor DNA reveals mechanisms of lorlatinib resistance in patients with relapsed/refractory ALK-driven neuroblastoma.,2023/May/05,"Pavlick, Dean; Goldsmith, Kelly C","Foundation Medicine, Inc, Cambridge, MA, USA.; Aflac Cancer and Blood Disorders Center, Children's Healthcare of Atlanta, Atlanta, GA, USA.",mosse@chop.edu.
37137552,Addressing resistance to PD-1/PD-(L)1 pathway inhibition: considerations for combinatorial clinical trial designs.,2023,"Ebbinghaus, Scot","Merck & Co Inc, Kenilworth, New Jersey, USA.",tian.zhang@utsouthwestern.edu.
37096188,Gumarontinib in patients with non-small-cell lung cancer harbouring ,2023,"Li, Meng","Biostatistic and Data Science, Haihe Biopharma Co., Ltd, Shanghai, China.",None
37069542,Overall survival in patients with advanced non-small cell lung cancer with KRAS G12C mutation with or without STK11 and/or KEAP1 mutations in a real-world setting.,2023/Apr/17,"Julian, Cristina; Pal, Navdeep; Gershon, Anda; Evangelista, Marie; Purkey, Hans; Lambert, Peter; Shi, Zhen; Zhang, Qing","1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA. shi.zhen@gene.com.; 1 DNA Way, Genentech, Inc, South San Francisco, CA, 94080, USA. zhangq47@gene.com.",zhangq47@gene.com.
37045997,Body composition and lung cancer-associated cachexia in TRACERx.,2023,"Collins, Susie","Early Clinical Development, Pfizer UK Ltd, Cambridge, UK.",Charles.swanton@crick.ac.uk.
37025260,A transcriptomics approach to expand therapeutic options and optimize clinical trials in oncology.,2023,"Zhang, Baolin","Office of Biotechnology Products (OBP), Center for Drug Evaluation and Research (CDER), Food and Drug Administration (FDA), Silver Spring, MA, USA.",None
37024582,Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer.,2023,"Rizvi, Naiyer","Synthekine, Inc., Menlo Park, CA, USA.",jgainor@mgh.harvard.edu.
37021770,Cost-effectiveness of adjuvant atezolizumab for patients with stage II-IIIA PD-L1+ non-small-cell lung cancer.,2023,"Ogale, Sarika; Jovanoski, Nick; Johnson, Ann; Nguyen, Caroline; Bhagwakar, Jan; Lee, Janet S","Genentech Inc, South San Francisco, CA 94080, USA.; F. Hoffmann-La Roche Ltd, 4070 Basel, Switzerland.; Genentech Inc, South San Francisco, CA 94080, USA.; Genentech Inc, South San Francisco, CA 94080, USA.; Genentech Inc, South San Francisco, CA 94080, USA.; Genentech Inc, South San Francisco, CA 94080, USA.",None
37003208,Real-world treatment patterns and outcomes of patients with metastatic nonsquamous non-small cell lung cancer after progression on standard-of-care therapy in the United States.,2023,"Divan, Hozefa A; Krishna, Ashok","Sanofi, Inc., 450 Water Street, Cambridge, MA 02142, USA. Electronic address: hozefa.divan@sanofi.com.; Sanofi, Inc., 450 Water Street, Cambridge, MA 02142, USA.",hozefa.divan@sanofi.com.
36961477,Supporting Biomarker-Driven Therapies in Oncology: A Genomic Testing Cost Calculator.,2023/May/08,"Cuffel, Brian; Paracha, Noman; Goodman, Clifford","Bayer Pharmaceuticals, Basel, Switzerland.; Bayer Pharmaceuticals, Basel, Switzerland.; The Lewin Group, Inc., Falls Church, VA, USA.",None
36947997,Cost-effectiveness analysis of adjuvant atezolizumab in stage II-IIIA non-small cell lung cancer expressing ≥50% PD-L1: A United Kingdom health care perspective.,2023,"Yip, Chui-Ying; Abogunrin, Seye; Belleli, Rossella; Di Maio, Danilo; Rouse, Peter; Jovanoski, Nick","Roche Products Ltd, Welwyn Garden City, United Kingdom. Electronic address: chui-ying.yip@roche.com.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Products Ltd, Welwyn Garden City, United Kingdom.; F. Hoffmann-La Roche Ltd, Basel, Switzerland.",chui-ying.yip@roche.com.
36947734,Initial Evidence for the Efficacy of Naporafenib in Combination With Trametinib in ,2023/May/10,"Gaur, Anil; Evans, Helen; Basu, Sumit","Novartis Healthcare Private Limited, Hyderabad, India.; Novartis Pharma AG, Basel, Switzerland.; Novartis Pharmaceuticals Corporation, East Hanover, NJ.",None
36944282,Use of radiation therapy among patients with Extensive-stage Small-cell lung cancer receiving Immunotherapy: Canadian consensus recommendations.,2023,"Greenland, Jonathan","Eastern Health, 300 Prince Philip Drive, St. John's, NL A1B 3V6, Canada. Electronic address: jonathan.greenland@easternhealth.ca.",geoffrey.liu@uhn.ca.
36927889,Predicting EGFR mutational status from pathology images using a real-world dataset.,2023/Mar/16,"Pao, James J; Biggs, Mikayla; Duncan, Daniel; Lin, Douglas I; Davis, Richard; Huang, Richard S P; Ferguson, Donna; Janovitz, Tyler; Hiemenz, Matthew C; Eddy, Nathanial R; Lehnert, Erik; Cabili, Moran N; Frampton, Garrett M; Hegde, Priti S; Albacker, Lee A","Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA.; Foundation Medicine Inc., 150 Second Street, Cambridge, MA, USA. lalbacker@foundationmedicine.com.",lalbacker@foundationmedicine.com.
36925916,Baseline risk factors associated with immune related adverse events and atezolizumab.,2023,"Maiya, Vidya","Product Development (PD), Genentech, Inc., South San Francisco, CA, United States.",None
36900371,"Treatment Patterns, Testing Practices, and Outcomes in Patients with ",2023/Mar/03,"Samborska, Agnieszka","AstraZeneca Pharma Poland Sp.zo.o., 02-676 Warsaw, Poland.",None
36866462,Variable Landscape of PD-L1 Expression in Breast Carcinoma as Detected by the DAKO 22C3 Immunohistochemistry Assay.,2023/Apr/06,"Danziger, Natalie; Sokol, Ethan S; Graf, Ryon P; Hiemenz, Matthew C; Maule, Jake; Parimi, Vamsi; Ross, Jeffrey S; Huang, Richard S P","Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.; Foundation Medicine, Inc., Cambridge, MA, USA.",None
36842467,MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy.,2023,"Olson, Peter; Latven, Lisa; Yan, Xiaohong; Shazer, Ronald","Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.; Mirati Therapeutics, Inc., San Diego, California.",kai.he@osumc.edu.
36841727,A Multicenter Retrospective Chart Review of Clinical Outcomes Among Patients With KRAS G12C Mutant Non-Small Cell Lung Cancer.,2023,"Sacher, Adrian","Princess Margaret Cancer Centre, Toronto, Ontario, Canada.",wade.t.iams@vumc.org.
36826141,Cost Savings of Expedited Care with Upfront Next-Generation Sequencing Testing versus Single-Gene Testing among Patients with Metastatic Non-Small Cell Lung Cancer Based on Current Canadian Practices.,2023/Feb/15,"Eaton, Kiefer; Emond, Bruno; Lafeuille, Marie-Hélène; Hilts, Annalise; Lefebvre, Patrick; Morrison, Laura; Stevens, Andrea L; Ewara, Emmanuel M","Janssen, Inc., Toronto, ON M3C 1L9, Canada.; Analysis Group, Inc., Montréal, QC H3B 0G7, Canada.; Analysis Group, Inc., Montréal, QC H3B 0G7, Canada.; Analysis Group, Inc., Montréal, QC H3B 0G7, Canada.; Analysis Group, Inc., Montréal, QC H3B 0G7, Canada.; Analysis Group, Inc., Montréal, QC H3B 0G7, Canada.; Janssen Global Services, Inc., Raritan, NJ 08869, USA.; Janssen, Inc., Toronto, ON M3C 1L9, Canada.",None
36822668,Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data.,2023,"Rossmann, Eva; Charo, Jehad","Roche Innovation Center Basel, F Hoffmann-La Roche Ltd, Basel, Switzerland.; Roche Innovation Center Zurich, F Hoffmann-La Roche Ltd, Schlieren, Switzerland jehad.charo@roche.com.",jehad.charo@roche.com.
36821595,RET Fusion-Positive Non-small Cell Lung Cancer: The Evolving Treatment Landscape.,2023/May/08,"Tamma, Antonella; Puri, Tarun","Medical Oncology, Eli Lilly and Company, Indianapolis, IN, USA.; Medical Oncology, Eli Lilly and Company, Indianapolis, IN, USA.",None
36809334,The role of macrophages in non-small cell lung cancer and advancements in 3D co-cultures.,2023/Feb/21,"Clevers, Hans","Roche Pharma Research and early Development, Basel, Switzerland.",None
36808075,SAFFRON-103: a phase 1b study of the safety and efficacy of sitravatinib combined with tislelizumab in patients with locally advanced or metastatic non-small cell lung cancer.,2023,"Li, Hui; Zhang, Juan; Peng, Yanyan","BeiGene (Shanghai) Co., Ltd, Shanghai, China.; BeiGene (Beijing) Co., Ltd, Beijing, China.; BeiGene (Shanghai) Co., Ltd, Shanghai, China.",syylwu@live.cn.
36751989,Real-world study of next-generation sequencing diagnostic biomarker testing for patients with lung cancer in Japan.,2023,"Emir, Birol; Iadeluca, Laura","Pfizer Inc., New York, USA.; Pfizer Inc., New York, USA.",None
36725084,"First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817.",2023,"Li, Sunney; Fiore, Joseph; Acevedo, Angelic","Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton, New Jersey, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.; Oncology Clinical Development, Bristol Myers Squibb, Princeton, New Jersey, USA.",neal.ready@duke.edu.
36689692,"Tarlatamab, a First-in-Class DLL3-Targeted Bispecific T-Cell Engager, in Recurrent Small-Cell Lung Cancer: An Open-Label, Phase I Study.",2023/Jun/01,"Zhang, Yiran; Pati, Amrita; Minocha, Mukul; Mukherjee, Sujoy; Goldrick, Amanda; Nagorsen, Dirk; Hashemi Sadraei, Nooshin","Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.; Amgen, Inc, Thousand Oaks, CA.",None
36669791,"Phase 1, open-label, dose-escalation study on the safety, pharmacokinetics, and preliminary efficacy of intravenous Coxsackievirus A21 (V937), with or without pembrolizumab, in patients with advanced solid tumors.",2023,"Hill, Andrew G; Jennens, Ross R; Ren, Yixin; Schmidt, Emmett V","Tasman Oncology Research Ltd, Southport, Queensland, Australia.; Epworth Healthcare, Richmond, Victoria, Australia.; Merck & Co., Inc, Rahway, New Jersey, USA.; Merck & Co., Inc, Rahway, New Jersey, USA.",rudinc@mskcc.org.
36657815,Venous thromboembolism incidence and risk factors associated with immune checkpoint inhibitors among patients with advanced non-small cell lung cancer.,2023,"Palaia, Jennell; Rosenblatt, Lisa; Pisupati, Radhika; Huang, Ning; Nguyen, Chi; Barron, John; Gallagher, Kerrin; Bond, T Christopher","Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA.; Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, New Jersey, USA.; US Medical Oncology, Bristol Myers Squibb, Princeton, New Jersey, USA.; Worldwide Patient Safety: Medical Safety Assessment, Bristol Myers Squibb, Princeton, New Jersey, USA.; Health Economics and Outcomes Research, HealthCore Inc, Wilmington, Delaware, USA.; Health Economics and Outcomes Research, HealthCore Inc, Wilmington, Delaware, USA.; Health Economics and Outcomes Research, HealthCore Inc, Wilmington, Delaware, USA.; Worldwide Patient Safety: Epidemiology, Bristol Myers Squibb, Princeton, New Jersey, USA.",khorana@ccf.org.
36651607,Bayesian hierarchical model-based network meta-analysis to overcome survival extrapolation challenges caused by data immaturity.,2023,"Chu, Haitao; Roychoudhury, Satrajit; Cappelleri, Joseph C","Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340, USA.; Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340, USA.; Pfizer Inc, 445 Eastern Point Road, MS 8260-2502, Groton, CT 06340, USA.",None
36650021,Durable responders in advanced NSCLC with elevated TMB and treated with 1L immune checkpoint inhibitor: a real-world outcomes analysis.,2023,"Huang, Richard S P; Li, Gerald; Schrock, Alexa; Graf, Ryon P; Zhang, Liangliang; Murugesan, Karthikeyan; Ross, Jeffrey S; Tolba, Khaled; Oxnard, Geoffrey R","Foundation Medicine Inc, Cambridge, Massachusetts, USA rhuang@foundationmedicine.com.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.; Foundation Medicine Inc, Cambridge, Massachusetts, USA.",rhuang@foundationmedicine.com.
36639770,Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012-2018.,2023/Jan/13,"Penrod, John R","Worldwide Health Economics and Outcomes Research, Bristol Myers Squibb, Princeton, NJ, USA.",andreayvonne.wolf@kgu.de.
36625510,Quality-of-life outcomes and risk prediction for patients randomized to nivolumab plus ipilimumab vs nivolumab on LungMAP-S1400I.,2023/Apr/11,"Summers, Thomas J","Cookeville Regional Medical Center, Southeast NCORP, Cookeville, TN, USA.",None
36606486,Multistate Pharmacometric Model to Define the Impact of Second-Line Immunotherapies on the Survival Outcome of the IMpower131 Study.,2023,"Mercier, François; Zhang, Rong; Wu, Ben; Jin, Jin Y; Bruno, René","Biostatistics, F. Hoffmann-La Roche Ltd., Basel, Switzerland.; Clinical Pharmacology, Genentech, South San Francisco, California, USA.; Clinical Pharmacology, Genentech, South San Francisco, California, USA.; Clinical Pharmacology, Genentech, South San Francisco, California, USA.; Clinical Pharmacology, Roche/Genentech, Marseille, France.",None
36595566,Tumor Dynamic Model-Based Decision Support for Phase Ib/II Combination Studies: A Retrospective Assessment Based on Resampling of the Phase III Study IMpower150.,2023/Mar/14,"Bruno, René; Yoshida, Kenta; Chan, Phyllis; Chanu, Pascal; Wu, Benjamin; Li, Chunze; Jin, Jin Y","Clinical Pharmacology, Genentech-Roche, Marseille, France.; Clinical Pharmacology, Genentech, South San Francisco, California.; Clinical Pharmacology, Genentech, South San Francisco, California.; Clinical Pharmacology, Genentech-Roche, Lyon, France.; Clinical Pharmacology, Genentech, South San Francisco, California.; Clinical Pharmacology, Genentech, South San Francisco, California.; Clinical Pharmacology, Genentech, South San Francisco, California.",None
38405208,High-dose alectinib for ,2023,"Alatorre-Alexander, Jorge; Bhagawati-Prasad, Vijay; Shagan, Sarah M; Schleifman, Erica; Ruf, Thorsten; Mathisen, Michael S","Health Pharma Professional Research, Mexico City, Mexico.; F. Hoffmann-La Roche, Ltd., Welwyn Garden City, UK.; Genentech, Inc., South San Francisco, CA, USA.; Genentech, Inc., South San Francisco, CA, USA.; F. Hoffmann-La Roche, Ltd., Basel, Switzerland.; Genentech, Inc., South San Francisco, CA, USA.",None
36571770,"Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF-β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.",2023/Mar/17,"Helwig, Christoph","Merck Healthcare KGaA, Darmstadt, Germany.",None
36484171,Baseline extracellular vesicle TGF-β is a predictive biomarker for response to immune checkpoint inhibitors and survival in non-small cell lung cancer.,2023/Feb/15,"Arroyo-Hernández, Marisol; Arrieta, Oscar","Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.; Thoracic Oncology Unit, Instituto Nacional de Cancerología (INCan), Mexico City, Mexico.",None
36460584,Budget impact analysis of next-generation sequencing versus sequential single-gene testing in Japanese patients with advanced non-small-cell lung cancer.,2023,"Ogawa, Toru; Sadatsuki, Yasunari; Tsujino, Toshiaki","Market Access Oncology, Bayer Yakuhin, Ltd, Osaka, Japan. Electronic address: toru.ogawa@bayer.com.; Medical Affairs & Pharmacovigilance, Bayer Yakuhin, Ltd, Osaka, Japan.; Medical Affairs & Pharmacovigilance, Bayer Yakuhin, Ltd, Osaka, Japan.",toru.ogawa@bayer.com.
36414192,Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small-cell lung cancer: a pooled analysis.,2023,"Memaj, A; Nathan, F","Global Biometrics and Data Sciences, Bristol Myers Squibb, Princeton.; OneClinical, Bristol Myers Squibb, Princeton.",hossein.borghaei@fccc.edu.
36403367,"Protective effect of obesity on survival in cancers treated with immunotherapy vanishes when controlling for type of cancer, weight loss and reduced skeletal muscle.",2023,"Voisin, Anne Laure; Messayke, Sabine; Laghouati, Salim","Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.; Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.; Unité de Pharmacovigilance, Gustave Roussy, Université Paris-Saclay, F-94800, Villejuif, France.",sami.antoun@gustaveroussy.fr.
36394849,Avelumab Plus Talazoparib in Patients With Advanced Solid Tumors: The JAVELIN PARP Medley Nonrandomized Controlled Trial.,2023/Jan/01,"Dvorkin, Michael","Clinical Oncology Dispensary, Budget Healthcare Institution of Omsk Region, Omsk, Russian Federation.",None
36369159,Surgical results of the Lung Cancer Mutation Consortium 3 trial: A phase II multicenter single-arm study to investigate the efficacy and safety of atezolizumab as neoadjuvant therapy in patients with stages IB-select IIIB resectable non-small cell lung cancer.,2023,"Nicholas, Alan; Schulze, Katja; Johnson, Ann","Genentech, Inc, South San Francisco, Calif.; Genentech, Inc, South San Francisco, Calif.; Genentech, Inc, South San Francisco, Calif.",ruschv@mskcc.org.
